Tubulis
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication
Pressemeldungen
HTGF Investment Tubulis
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug…
Info & Contact
- E-mail:
- info@tubulis.com
- Web:
- www.tubulis.com
Address
Tubulis GmbH
Butenandtstraße 1
81377 Munich
Germany
Butenandtstraße 1
81377 Munich
Germany
In portfolio
17. Jul 2020